Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties

Ganoderma lucidum (рейши), съедобный гриб: всесторонний и критический обзор его пищевых, космецевтических, микохимических, фармакологических, клинических и токсикологических свойств
Muhammad Riaz, Rizwan Ahmad, Aslam Khan, Ahmed Aljamea, Mohammad Algheryafi, Deya Sewaket, Aljawharah A. Alqathama
2021-08-19

Ganoderma lucidumReishi mushroompharmacological activitiespolysaccharidestriterpenoids
Reishi owes an exceptional value in nutritional, cosmeceutical, and medical treatments; however, none of the studies has provided its future-driven critical assessment. This study documents an up-to-date review (2015-2020, wherever applicable) and provide valuable insights (preclinical and clinical evidence-based) with comprehensive and critical assessments. Various databases 'Google scholar', 'Web of Science', 'ScienceDirect', 'PubMed', 'Springer Link', books, theses, and library resources were used. The taxonomic chaos of G. lucidum and its related species was discussed in detail with solution-oriented emphasis. Reishi contains polysaccharides (α/β-D-glucans), alkaloids, triterpenoids (ganoderic acids, ganoderenic acids, ganoderol, ganoderiol, lucidenic acids), sterols/ergosterol, proteins (LZ-8, LZ-9), nucleosides (adenosine, inosine, uridine), and nucleotides (guanine, adenine). Some active drugs are explored at an optimum level to make them potential drug candidates. The pharmacological potential was observed in diabetes, inflammation, epilepsy, neurodegeneration, cancer, anxiety, sedation, cardiac diseases, depression, hepatic diseases, and immune disorders; however, most of the studies are preclinical with a number of drawbacks. In particular, quality clinical data are intensely needed to support pharmacological activities for human use. The presence of numerous micro-, macro, and trace elements imparts an essential nutritional and cosmeceutical value to Reishi, and various marketed products are available already, but the clinical studies regarding safety and efficacy, interactions with foods/drinks, chronic use, teratogenicity, mutagenicity, and genotoxicity are missing for Reishi. Reishi possesses many valuable pharmacological activities, and the number of patents and clinical trials is increasing for Reishi. Yet, a gap in research exists for Reishi, which is discussed in detail in the forthcoming sections.
1
Most pharmacological evidence remains preclinical, and robust clinical data are needed to establish efficacy and support human therapeutic use.
2
Preclinical studies report potential benefits in diabetes, inflammation, epilepsy, neurodegeneration, cancer, anxiety, sedation, cardiac, depressive, hepatic, and immune disorders.
3
Reishi contains diverse bioactive constituents, including α/β-D-glucans, triterpenoids, sterols, proteins, nucleosides, nucleotides, and multiple nutritional elements.
4
Safety and efficacy evidence is lacking for chronic use, food or drink interactions, teratogenicity, mutagenicity, and genotoxicity, despite increasing products, patents, and clinical trials.
5
The review critically synthesizes 2015–2020 evidence on Reishi’s nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties.

Ganoderma lucidum (Reishi) mushroom

The nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties, activities, and safety of Reishi

Publication Details
Publication Date
2021-08-19
Journal
Publisher
ISSN
Cited by
191
Access Type
Author Information
Authors
Muhammad Riaz
Rizwan Ahmad
Aslam Khan
Ahmed Aljamea
Mohammad Algheryafi
Deya Sewaket
Aljawharah A. Alqathama
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%